BELLWAVE-010: A phase 3 study of nemtabrutinib plus venetoclax versus venetoclax plus rituximab (VR) in previously treated patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
Authors: Muhit Ozcan, David Lavie, Arvind Chaudhry, Xuan Zhou, Ima Paydar, Mohammed Z.H. Farooqui, Paolo Ghia
Journal: Journal of Clinical Oncology (2024)

TPS7089 Background: VR is a standard of care option for pts with CLL/SLL who have relapsed after ≥1 line of prior therapy. However, there is an unmet need for more effective treatments. Bruton tyrosine kinase (BTK) plays an important role in the pathogenesis of CLL. Nemtabrutinib is a BTK inhibitor that targets both wild type and C481-mutant forms of BTK. In the ongoing BELLWAVE-001 study, nemtabrutinib demonstrated manageable safety and durable antitumor activity in pts with R/R CLL/SLL with and without C481 mutations. The randomized, open-label, phase 3 BELLWAVE-010 study (NCT05947851) is designed to evaluate the efficacy and safety of nemtabrutinib + venetoclax versus VR as second-line or later treatment for pts with R/R CLL/SLL. Methods: Eligible pts are aged ≥18 years with active R/R CLL/SLL after ≥1 prior therapy per iwCLL 2018 criteria and an ECOG PS of 0-2. Approximately 720 pts will be enrolled in 2 parts. Part 1 is an open-label, nonrandomized dose escalation and confirmation phase to evaluate safety and determine the optimal dose of nemtabrutinib + venetoclax. Part 1 will enroll 30 pts to establish the dose of nemtabrutinib using a modified toxicity probability interval design. Pts will receive nemtabrutinib at 2 dose levels (45 mg PO QD starting dose, escalating to 65 mg PO QD) for 28 days, followed by nemtabrutinib + venetoclax (20-400 mg PO QD ramp up over 4 weeks). Part 2 is an open-label, parallel-group, randomized phase comparing the efficacy and safety of nemtabrutinib + venetoclax with VR. In part 2, approximately 690 pts will be randomly assigned 1:1 to receive either nemtabrutinib at the recommended dose for 28 days followed by the nemtabrutinib + venetoclax or venetoclax + rituximab (or rituximab biosimilar; 375 mg/m 2 at week 6, followed by 500 mg/m 2 every 4 weeks starting at week 10 until week 26 [total 6 doses]). Study treatment will continue for approximately 2 years or until unacceptable toxicity, disease progression, or other discontinuation criteria are met. Randomization will be stratified by BTK-C481 mutation status (detected vs not detected), geographic region (US/Canada vs Europe vs rest of world) and risk (high risk [del(17p) and/or TP53-mutated and/or IGHV-unmutated] vs low risk [absence of high-risk factors]). The primary end point for part 2 is progression-free survival by blinded independent central review (BICR) per iwCLL 2018 criteria. Secondary end points for part 2 are undetectable minimal residual disease in bone marrow at month 14 by central laboratory assessment, objective response rate (ORR), and duration of response by BICR per iwCLL 2018 criteria, overall survival, and safety. Exploratory end points are ORR including partial response with lymphocytosis, pharmacokinetics, and health-related quality of life. Recruitment is ongoing. Clinical trial information: NCT05947851 .